Ortho Clinical Diagnostics Holdings plc (OCDX) Financial Statements (2026 and earlier)

Company Profile

Business Address 1001 ROUTE 202
RARITAN, NJ 08869
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)
Annual | Quarterly

3/31/2022
MRQ
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 310
Cash and cash equivalent 310
Receivables 257
Inventory, net of allowances, customer advances and progress billings 305
Inventory 305
Other current assets 139
Total current assets: 1,012
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization 791
Intangible asset, including goodwill, after accumulated amortization 1,453
Goodwill 574
Intangible asset, excluding goodwill, after accumulated amortization 879
Deferred income tax assets 10
Other noncurrent assets 98
Total noncurrent assets: 2,352
TOTAL ASSETS: 3,364
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 481
Accounts payable 181
Accrued liabilities 300
Deferred revenue 35
Debt 63
Total current liabilities: 579
Noncurrent Liabilities
Long-term debt and lease obligation, including: 2,187
Other undisclosed long-term debt and lease obligation 2,187
Liabilities, other than long-term debt 188
Deferred income tax liabilities 72
Liability, pension and other postretirement and postemployment benefits 37
Other liabilities 79
Total noncurrent liabilities: 2,375
Total liabilities: 2,953
Equity
Equity, attributable to parent 411
Preferred stock 0
Additional paid in capital 2,426
Accumulated other comprehensive loss (44)
Accumulated deficit (1,972)
Total equity: 411
TOTAL LIABILITIES AND EQUITY: 3,364

Income Statement (P&L) ($ in millions)
Annual | Quarterly

3/31/2022
TTM
12/31/2021
Revenues 2,043
Cost of revenue (1,007)
Gross profit: 1,036
Operating expenses (555)
Other operating expense, net (48)
Other undisclosed operating loss (260)
Operating income: 174
Nonoperating expense
(Other Nonoperating expense)		 (53)
Interest and debt expense (196)
Loss from continuing operations before equity method investments, income taxes: (76)
Other undisclosed income from continuing operations before income taxes 50
Loss from continuing operations before income taxes: (26)
Income tax expense (28)
Loss from continuing operations: (54)
Loss before gain (loss) on sale of properties:✕(54)
Net loss available to common stockholders, diluted: (54)

Comprehensive Income ($ in millions)
Annual | Quarterly

3/31/2022
TTM
12/31/2021
Net loss: (54)
Other comprehensive income 25
Comprehensive loss, net of tax, attributable to parent: (30)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios